Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 6/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188878 | 0.83 | SMYD2 (0.37) | SMYD2SMN1; SMN2LMNAALDH1A1BLM | |
| SCHEMBL17496700 | 0.83 | SMYD2 (0.33) | SMYD2SMN1; SMN2LMNAALDH1A1BLM | |
| SCHEMBL3638318 | 0.81 | SMYD2 (0.36) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL3456559 | 0.80 | SMYD2 (0.36) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL31092036 | 0.79 | SMYD2 (0.37) | SMYD2SMN1; SMN2ALDH1A1CYP3A4HTT | |
| SCHEMBL9468934 | 0.79 | CYP3A4 (0.33) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL3262971 | 0.79 | CYP3A4 (0.35) | SMYD2SMN1; SMN2ALDH1A1CYP3A4HTT | |
| SCHEMBL6795155 | 0.79 | CYP3A4 (0.35) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL9468930 | 0.79 | CYP3A4 (0.33) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL17093480 | 0.78 | SMYD2 (0.34) | SMYD2SMN1; SMN2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120157686-A | Compound with AKT kinase degradation activity, preparation method and pharmaceutical application thereof | 南京正大天晴制药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-118994171-A | Preparation method of rebamacinib intermediate 2-chloro-7-cyclopentyl-7H-pyrrolo [2,3-d ] pyrimidine-6-methanol | 浙江工业大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2011106997-A1 | NOVEL 10-23 DEOXYRIBOZYME ANALOGUES AND USES THEREOF | 中国人民解放军军事医学科学院毒物药物研究所 (CN) | 2011-09-09 | — | — | WO | disclosed |
| WO-2007134421-A1 | 2-VINYL INDOLES, PYRIDO AND AZEPINO INDOLE DERIVATIVES, 2-ALKYNYL INDOLES, 2-ALKYNYL BENZO[b]FURANS, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2007-11-29 | — | — | WO | disclosed |
| US-5527805-A | DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0523151-B1 | TRANSMETALATIONS FROM ZIRCONIUM TO COPPER INTERMEDIATES | UNIV CALIFORNIA (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5286889-A | Reacting 1-alkyne with zirconocene chloride hydride, reacting product with organic lithium compound, reacting with lithium cuprate compound | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-02-15 | — | — | US | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| US-5072010-A | Reacting zirconium and lithium compounds, reacting product with copper/lithium complex | UNIVERSITY OF CALIFORNIA (US) | 1991-12-10 | — | — | US | disclosed |
| US-4959391-A | LIPOXYGENASE INHIBITORS, LEUKOTRIENE DISEASES | GRUENENTHAL GMBH (DE) | 1990-09-25 | — | — | US | disclosed |
| US-4760087-A | 5-lipoxygenase inhibitor | GRUENENTHAL GMBH (DE) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | SMYD2 623/4885SMN1; SMN2 751/4885LMNA 2987/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | SMYD2 1157/4885SMN1; SMN2 2179/4885LMNA 1553/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | SMYD2 2274/4885SMN1; SMN2 2529/4885LMNA 2729/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | SMYD2 569/4885SMN1; SMN2 326/4885LMNA 746/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | SMYD2 1950/4885SMN1; SMN2 2678/4885LMNA 2259/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | SMYD2 623/4885SMN1; SMN2 751/4885LMNA 2987/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | SMYD2 2274/4885SMN1; SMN2 2529/4885LMNA 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.